These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31173643)

  • 21. MiR-132-3p serves as a tumor suppressor in mantle cell lymphoma via directly targeting SOX11.
    Wu B; Li J; Wang H; Wu Q; Liu H
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2197-2208. PubMed ID: 32040593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of V-ATPase as a molecular sensor of SOX11-levels and potential therapeutic target for mantle cell lymphoma.
    Emruli VK; Olsson R; Ek F; Ek S
    BMC Cancer; 2016 Jul; 16():493. PubMed ID: 27430213
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma.
    Vegliante MC; Palomero J; Pérez-Galán P; Roué G; Castellano G; Navarro A; Clot G; Moros A; Suárez-Cisneros H; Beà S; Hernández L; Enjuanes A; Jares P; Villamor N; Colomer D; Martín-Subero JI; Campo E; Amador V
    Blood; 2013 Mar; 121(12):2175-85. PubMed ID: 23321250
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Expression of myocyte enhancer factor 2B in mantle cell lymphoma and its clinical significance].
    Liu F; Liu Q; Guo N; Zhang GM; Deng YF; Hu WW; Rao HL
    Zhonghua Bing Li Xue Za Zhi; 2020 Jan; 49(1):40-46. PubMed ID: 31914533
    [No Abstract]   [Full Text] [Related]  

  • 25. miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11.
    Zhou K; Feng X; Wang Y; Liu Y; Tian L; Zuo W; Yi S; Wei X; Song Y; Qiu L
    Exp Hematol; 2018 Feb; 58():27-34.e1. PubMed ID: 29158064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma.
    Balsas P; Veloza L; Clot G; Sureda-Gómez M; Rodríguez ML; Masaoutis C; Frigola G; Navarro A; Beà S; Nadeu F; Giné E; López-Guillermo A; Martínez A; Ribera-Cortada I; Engel P; Quintanilla-Martínez L; Klapper W; Campo E; Amador V
    Blood; 2021 Dec; 138(22):2202-2215. PubMed ID: 34189576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study.
    Nordström L; Sernbo S; Eden P; Grønbaek K; Kolstad A; Räty R; Karjalainen ML; Geisler C; Ralfkiaer E; Sundström C; Laurell A; Delabie J; Ehinger M; Jerkeman M; Ek S
    Br J Haematol; 2014 Jul; 166(1):98-108. PubMed ID: 24684350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SOX11 augments BCR signaling to drive MCL-like tumor development.
    Kuo PY; Jatiani SS; Rahman AH; Edwards D; Jiang Z; Ahr K; Perumal D; Leshchenko VV; Brody J; Shaknovich R; Ye BH; Parekh S
    Blood; 2018 May; 131(20):2247-2255. PubMed ID: 29615403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype.
    Ribera-Cortada I; Martinez D; Amador V; Royo C; Navarro A; Beà S; Gine E; de Leval L; Serrano S; Wotherspoon A; Colomer D; Martinez A; Campo E
    Mod Pathol; 2015 Nov; 28(11):1435-47. PubMed ID: 26360498
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Flow cytometric analysis of SOX11: a new diagnostic method for distinguishing B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma from mantle cell lymphoma.
    Wasik AM; Priebe V; Lord M; Jeppsson-Ahlberg Å; Christensson B; Sander B
    Leuk Lymphoma; 2015 May; 56(5):1425-31. PubMed ID: 25120048
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SOX11 as a minimal residual disease marker for Mantle cell lymphoma.
    Simonsen AT; Sørensen CD; Ebbesen LH; Bødker JS; Bentzen HH; Nyvold CG
    Leuk Res; 2014 Aug; 38(8):918-24. PubMed ID: 24878000
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Highly sensitive and specific
    Federmann B; Frauenfeld L; Pertsch H; Borgmann V; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
    Haematologica; 2020 Mar; 105(3):754-764. PubMed ID: 31296581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma.
    Kuo PY; Leshchenko VV; Fazzari MJ; Perumal D; Gellen T; He T; Iqbal J; Baumgartner-Wennerholm S; Nygren L; Zhang F; Zhang W; Suh KS; Goy A; Yang DT; Chan WC; Kahl BS; Verma AK; Gascoyne RD; Kimby E; Sander B; Ye BH; Melnick AM; Parekh S
    Oncogene; 2015 Mar; 34(10):1231-40. PubMed ID: 24681958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SOXC and MiR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma.
    Roisman A; Huamán Garaicoa F; Metrebian F; Narbaitz M; Kohan D; García Rivello H; Fernandez I; Pavlovsky A; Pavlovsky M; Hernández L; Slavutsky I
    Genes Chromosomes Cancer; 2016 Jun; 55(6):531-40. PubMed ID: 26998831
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases.
    Veselá P; Tonar Z; Sálek D; Vokurka S; Trněný M; Kodet R; Moulis M; Kašparová P; Vernerová Z; Velenská Z; Stříteský J; Michal M; Boudová L
    Virchows Arch; 2014 Nov; 465(5):587-97. PubMed ID: 25048573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma.
    Sureda-Gómez M; Balsas P; Rodríguez ML; Nadeu F; De Bolòs A; Eguileor Á; Kulis M; Castellano G; López C; Giné E; Demajo S; Jares P; Martín-Subero JI; Beà S; Campo E; Amador V
    Leukemia; 2023 Feb; 37(2):408-421. PubMed ID: 36509891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. SOX11 is useful in differentiating cyclin D1-positive diffuse large B-cell lymphoma from mantle cell lymphoma.
    Hsiao SC; Cortada IR; Colomo L; Ye H; Liu H; Kuo SY; Lin SH; Chang ST; Kuo TU; Campo E; Chuang SS
    Histopathology; 2012 Oct; 61(4):685-93. PubMed ID: 22642745
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma.
    De Bolòs A; Sureda-Gómez M; Carreras-Caballé M; Rodríguez ML; Clot G; Beà S; Giné E; Campo E; Balsas P; Amador V
    Sci Rep; 2024 Apr; 14(1):7863. PubMed ID: 38570586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma.
    Hamborg KH; Bentzen HH; Grubach L; Hokland P; Nyvold CG
    Eur J Haematol; 2012 Nov; 89(5):385-94. PubMed ID: 22827557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma.
    Nygren L; Baumgartner Wennerholm S; Klimkowska M; Christensson B; Kimby E; Sander B
    Blood; 2012 May; 119(18):4215-23. PubMed ID: 22431568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.